In seven years, a small company has built two programs in immuno-oncology and molecular glues and got itself into a partnership with one of the world’s biggest pharma companies. Now the transatlantic biotech has refilled its coffers. Orionis Biosciences announced Wednesday morning that it finished a Series C round and secured $55 million. That infusion... Learn more The post Novartis-partnered Orionis secures $55M to push cytokine program into clinic appeared first on Orionis Biosciences.
